Senicapoc

Last updated
Senicapoc
Senicapoc.png
Names
Preferred IUPAC name
2,2-Bis(4-fluorophenyl)-2-phenylacetamide
Identifiers
3D model (JSmol)
ChemSpider
KEGG
PubChem CID
UNII
  • InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24) X mark.svgN
    Key: SCTZUZTYRMOMKT-UHFFFAOYSA-N X mark.svgN
  • InChI=1/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
    Key: SCTZUZTYRMOMKT-UHFFFAOYAR
  • C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
Properties
C20H15F2NO
Molar mass 323.34 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Senicapoc (ICA-17043) is a Gardos channel blocker. [1] [2]

It has been proposed for use in sickle cell anemia. [3] Gardos channel blockers may work in the treatment of sickle cell anemia by blocking the efflux of potassium and water from red blood cells, thereby preventing the dehydration of red blood cells and stopping the polymerization of HbS.

The Gardos channel has been identified as KCNN4. [4]

The "ICA" is for Icagen, which is developing the drug. [5]

References

  1. ↑ Ataga KI, Smith WR, De Castro LM, et al. (April 2008). "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood. 111 (8): 3991–7. doi: 10.1182/blood-2007-08-110098 . PMID   18192510.
  2. ↑ McNaughton-Smith GA, Burns JF, Stocker JW, et al. (February 2008). "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. doi:10.1021/jm070663s. PMID   18232633.
  3. ↑ Ataga KI; Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs. 18 (2): 231–9. doi:10.1517/13543780802708011. PMID   19236269. S2CID   73061898.
  4. ↑ Hoffman JF; Joiner W; Nehrke K; Potapova O; Foye K; Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. Bibcode:2003PNAS..100.7366H. doi: 10.1073/pnas.1232342100 . PMC   165881 . PMID   12773623.
  5. ↑ "Icagen - Press Release" . Retrieved 2008-12-22.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.